Literature DB >> 10896269

Muscle autoantibodies in subgroups of myasthenia gravis patients.

F Romi1, G O Skeie, J A Aarli, N E Gilhus.   

Abstract

Myasthenia gravis (MG) is caused by autoantibodies to the acetylcholine receptor (AChR), but several other muscle autoantibodies have also been identified in patient sera. We studied muscle autoantibodies against AChR, striated muscle tissue sections (SH), titin, citric acid antigen (CA), and ryanodine receptor (RyR) in sera from 146 consecutive MG patients to evaluate whether a single test or several tests together can predict a thymoma. The MG patients were divided into five subgroups; ocular MG, early-onset MG (< 50 years), late-onset MG (> 50 years), MG with thymoma, and AChR antibody negative MG. AChR, SH, titin, CA, and RyR antibodies were detected in 85%, 34%, 34%, 25%, and 14% of the MG patients, respectively. For thymoma MG, AChR, SH, titin, CA, and RyR antibodies were detected in 100%, 75%, 95%, 70%, and 70% respectively. SH, titin, CA, RyR antibodies, and computed tomography of the anterior mediastinum have similar sensitivity for thymoma MG. The specificity of RyR, titin, CA, and SH antibodies for thymoma was 70%, 39%, 38%, and 31%, respectively, which is significantly higher for RyR antibodies than for the others. No single muscle antibody assay can predict a thymoma, and a combination of several antibody assays is preferred, although RyR antibody testing alone showed 70% sensitivity and specificity for thymoma MG. SH and CA antibodies provided only little additional information.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896269     DOI: 10.1007/s004150050604

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  14 in total

1.  Quality of life and life circumstances in German myasthenia gravis patients.

Authors:  Sabine Twork; Susanne Wiesmeth; Jörg Klewer; Dieter Pöhlau; Joachim Kugler
Journal:  Health Qual Life Outcomes       Date:  2010-11-11       Impact factor: 3.186

Review 2.  Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.

Authors:  Elizabeth A Lippner; David B Lewis; William H Robinson; Tamiko R Katsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-06-22

3.  Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

Authors:  J F Owe; A K Daltveit; N E Gilhus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

4.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

5.  Postoperative myasthenic crisis successfully treated with immunoadsorption therapy.

Authors:  Junko Ishizeki; Koichi Nishikawa; Fumio Kunimoto; Fumio Goto
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

6.  Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.

Authors:  Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys
Journal:  J Neurol       Date:  2017-05-17       Impact factor: 4.849

7.  The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis.

Authors:  Xiang-Jun Chen; Jian Qiao; Bao-Guo Xiao; Chuan-Zhen Lu
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

Review 8.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 9.  Myasthenia gravis and thymic neoplasms: A brief review.

Authors:  Ritesh Kumar
Journal:  World J Clin Cases       Date:  2015-12-16       Impact factor: 1.337

10.  Thymoma in myasthenia gravis: from diagnosis to treatment.

Authors:  Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.